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Available online 12 September 2016Background: Naive T lymphocytes recirculate through the body, traveling from secondary lymphoid organs
through tissues and via lymphatic vessels and peripheral blood into other secondary lymphoid organs and into
the bonemarrow. In these tissues, lymphocytes are exposed to the chemokine CXCL12which is abundantly pro-
duced in bonemarrow and in lymph nodes by stromal cells. CXCL12 is known to drive lymphocytes chemotaxis
and, in cells types such as stem cells, an antiapopototic effect has been described.
Methods: Here we analyzed the effect of CXCL12 exposure on naïve CD4+ T lymphocytes puriﬁed from peripheral
blood by immunomagnetic negative isolation and cultured in a nutrient poor medium. We also studied, mainly by
western blot analysis, the signaling pathways involved in CXCL12 action on naïve CD4+ T lymphocytes.
Results:We found that CXCL12-exposed cells survived longer than untreated ones and this prolonged lifespan was
speciﬁc for resting naïve lymphocytes, while in vitro activated lymphoblasts died rapidly despite CXCL12 treatment.
Wedemonstrated that the increased percentage of living cells observed uponCXCL12 administrationwas not due to
induction of proliferation but to a prosurvival effect of this chemokine. Moreover, our data suggest that this
prosurvival effect on naïve CD4+ T lymphocytes might likely be mediated by PKA-dependent CREB activation
and consequent increased expression of the antiapoptotic factors Bcl2 and BclXl.
Conclusions: This newly reported activity of CXCL12might contribute to themaintenance of the naïve T lymphocytes
pool in vivo, which is needed to ensure a proper immune response to new antigens.






Complex patient rehabilitation1. Introduction
Maintaining the naive T lymphocytes pool is essential to ensure an
optimal immune response against novel antigens [1]. After intrathymic
maturation, naive T cells colonize the periphery and recirculate through
lymphoid organs until they encounter their speciﬁc antigen. Following
antigen recognition, activation of naive T cells (characterized by pheno-
type changes and clonal expansion) occurs. This phase is then followed
by contraction, so that the total number of peripheral cells remains in
homeostatic equilibrium [2–6]. Lymphocytes that do not encounter
their speciﬁc antigen continue to recirculate, keeping their naive pheno-
type. Despite thymic involutionwhich begins early in the childhood, the
proportion of circulating naive T cells remains relatively constant during
adulthood [7]. This homeostasis is thought to be maintained by tworraro).
.main mechanisms: persistent thymic output of newly generated naive
cells [8] and expansion of naive lymphocytes in the periphery [9].
Both thesemechanisms have been conﬁrmed by several studies includ-
ed the detection of TCR excision circles (TRECs) in the peripheral blood
of the elderly [10,11]. Along with these mechanisms, lifespan of resting
naive T cells might also play a role in ensuring the maintenance of an
untouched naive T lymphocytes pool.
CXCL12, also known as SDF-1α, is a widely studied chemokine, ﬁrst-
ly described as growth factor for pre-B cells [12,13]. CXCL12 acts as a
chemoattractant for T lymphocytes, monocytes and dendritic cells,
and drives their homing to lymphoid organs [14]. It is abundantly pro-
duced in the bonemarrow by stromal cells and CXCL12-abundant retic-
ular cells (CAR) [15], and by stromal cells in lymph nodes [16]. Besides its
function as a chemokine, CXCL12 has been demonstrated to have a co-
stimulatory effect on T lymphocytes [17,18] and a cell type-dependent
role in the apoptosis; in fact, it induces apoptosis of neurons [19] but
has a pro-survival effect on stem cells [20] and granulosa cells in the
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served seven transmembrane G protein coupled receptor (GPRC) ex-
clusive for CXCL12. The activation of CXCR4 by CXCL12 is mediated
by a heterotrimeric G-protein, containing a Gαi and a Gβγ subunit [22].
Gαi activation results in release of calcium via PLCβ as well as inhibition
of adenyl cyclase (AC)-mediated cyclic adenosine monophosphate
(cAMP) production [22]. CXCR4 stimulation induces calcium inﬂux
[23], the Ras–RAF–MEK–ERK [24] and the PI3K–AKT–NFkB [25] signal-
ing cascades.
Alterations in the homeostasis of lymphocytes, in particular the
decreased number of naive T lymphocytes and an inverted CD4/CD8
ratio are correlated with an increased incidence of infections [26]
which have a relevant impact, among the others, on aged individuals
and during rehabilitation. Therefore, unraveling the mechanisms that
contribute to the maintenance of homeostasis could help to identify
strategies to reduce the incidence of infections inmedically complex pa-
tients. Here, we analyzed the survival rate of isolated naive CD45RA+
CD4+ T lymphocytes, exposed to CXCL12 and we observed, for the
ﬁrst time to our knowledge, that CXCL12 greatly prolongs the survival
of CD4+ naive T lymphocytes cultured in a nutrient poor medium.
This effect was speciﬁc for resting naive T cells and seems to be mediat-
ed by a PKA-dependent CREB activation and by an increased expression
of the anti-apoptotic factors Bcl2 and BclXl.
2. Materials and methods
2.1. Lymphocytes isolation and cell culture
CD4+ CD45RA+ T lymphocytes were separated from peripheral blood mononuclear
cells (PBMC). Leukocyte-enriched buffy coat from healthy donors were provided by the
transfusion centre of Azienda Ospedaliera Universitaria Federico II. Written informed
consent was obtained from each donor at the time of venous peripheral blood donation, in
accordance with the Declaration of Helsinki, as approved by Azienda Ospedaliera
Universitaria Federico II. All the experiments done by using blood donationswere performed
and analyzed anonymously, without any biographical reference to donors. Brieﬂy, PBMC
were obtained from buffy coats by centrifugation on a Ficoll-Hypaque plus (GE Healthcare,
Milan, Italy) density gradient. PBMC were washed in PBS and CD4+ CD45RA+ T cells
were isolated using the Naive CD4+ T Cell Isolation Kit II, (Miltenyi Biotech, Calderara di
Reno, Italy), according to manufacturer's instruction. Activated lymphoblasts were obtained
from naive T cells cultured for three days in complete medium (RPMI plus 10% FBS, 2 mM
L-Glutamine, 1% Sodium Piruvate, 1% Non essential amino acids, 1% penicillin/streptomycin,
all from ThermoFisher, Milan, Italy) in the presence of 2 μg/ml PHA (Sigma, Milan, Italy)
and 20 U/ml IL-2 (Peprotech, Rocky Hill, NJ, USA). Cells were then cultured in RPMI
(ThermoFisher, Milan, Italy) medium supplemented with 2% FBS (ThermoFisher, Milan,
Italy) and 1% penicillin/streptomycin, with or without the adding of 100 ng/ml of SDF-1α/
CXCL12 (Peprotech, Rocky Hill, NJ, USA). PD98059, H89 and 8-Bromoadenosine 3′,5′-cyclic
monophosphate (8-Br-cAMP) were purchased from Sigma-Aldrich (Milan, Italy). Cells
were harvested at appropriated time points and analyzed by ﬂow cytometry.
2.2. Flow cytometry analysis
Cells were stained with FITC conjugated anti CD45RA, PE conjugated anti CXCR4,
PECy5 conjugated anti CD4 and APC conjugated anti CD3, all from Becton Dickinson
(Milan, Italy). For propidium iodide (PI) staining, 2 × 105 cells were harvested at appropri-
ate time points and 1 μg/ml PI (eBioscience, SanDiego, CA)was added. Cellswere acquired
immediately after adding of PI. Acquisition and analysis were performed on a FACScalibur
ﬂow cytometer (Becton Dickinson) using CellQuest software.
2.3. Proliferation assay
Cell cultures were prepared in triplicate in microtiter plates. 100,000 cells were cul-
tured for 72 h in the presence of anti CD3-coated magnetic beads (ThermoFisher, Milan,
Italy), with or without 100 ng/ml soluble CXCL12. Anti CD3/CD28 coated magnetic
beadswere used as a positive control of proliferation. [3H] Thymidine (Amersham Interna-
tional, Amersham, GB) was added to cultures during the last 6 h of incubation. Cells were
then harvested (Tomtec) and radioactivity was measured with a betaplate scintillation
counter (Wallac).
2.4. Western blot analysis
1×106 puriﬁedCD4CD45RAcells or activated lymphoblastswere incubated at 37 °C for
different periods of timewith CXCL12 at the concentrations indicated inﬁgure legends, PMA/
Ionomycin (50 ng/ml and 1 μg/ml respectively, both from Sigma Aldrich), or left alone. Lym-
phocytes were lysed in 50mMTris/HCl, pH 7.4, 150mMNaCl, 0.1% Nonidet P-40, 100 μg/ml
phenylmethylsulfonyl ﬂuoride, 100 μg/ml tosylphenylalanine chloromethyl ketone, 1 μg/mlleupeptin, 0.83 μg/ml chymostatin, 10 μg/ml soybean trypsin inhibitor, 1 mM sodium
orthovanadate, and 0.5 mM dithiothreitol. The lysates were boiled for 5 min and separated
on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Western blot analysis was
performed using mAb to phospho-ERK1,2, ERK-1,2, phospho-CREB, Bcl2, BclXl, and β-actin
(all from Santa Cruz Biotechnology, Santa Cruz, CA) and was developed using the
SuperSignal™West Pico Chemiluminescent Substrate (ThermoFisher, Milan, Italy).
2.5. Statistical analysis
Statistical analysis were performed using Prism 5 software (GraphPad), using two-
way Anova or Mann Whitney Test. All experiments were performed at least three times
using cells from different donors.
3. Results
3.1. CXCL12 enhances naive T lymphocytes viability
To evaluate the ability of CXCL12 to induce long-lasting biological
effects on naive T lymphocytes, we puriﬁed resting naïve CD4+
CD45RA+ lymphocytes from healthy donor's peripheral blood and
we cultured them in a nutrient-poor medium in presence or absence
of CXCL12. We evaluated naïve CD4+ CD45RA+ lymphocyte viability
by ﬂow cytometry every other day from day 1 to day 9 (Fig. 1A and B)
by means of both propidium iodide (PI) staining (Fig. 1A) and changes
in cell dimension and complexity (Fig. 1B). We observed that CXCL12-
treated naïve CD4+ lymphocytes survived longer in a nutrient-poor
medium compared to untreated cells. This effect was evident consider-
ing both the percentage of PI negative cells and cell morphology chang-
es. In fact, at day 7, for example, only 20% of the untreated cells were PI
negative (Fig. 1A; graph), compared to the 54% of CXCL12-treated cells
(Fig. 1B; graph) (p b 0.001, n = 6), and the percentage of living cells
based on morphological features was 52% for CXCL12-treated lympho-
cytes versus 27% for untreated controls (p b 0.001, n = 9). Notably,
these data show the similarity of the results obtained by the two
methods we used for cell survival detection. We then asked whether
this effect was speciﬁc for naïve cells, or was common also to activated
lymphocytes. To address this point we generated proliferating lympho-
blasts by incubating naïve CD4+ T lymphocytes with PHA and IL-2 for
3 days. Lymphoblasts were then washed and cultured in 2% FBS medi-
um, and their viability was evaluated every other day from day 1 to
day 9 by analyzing cells morphology by ﬂow cytometry (Fig.1C). To
note, survival of activated blasts was decreased compared to naïve
cells (Fig. 1B untr vs Fig. 1C untr), being lymphoblast survival percent-
age less than 60% by day 1, while CD4+ T lymphocytes survival per-
centage was 80% by the same day. More importantly, our experiments
displayed that CXCL12 treatment did not increase the survival of prolif-
erating lymphoblasts (Fig. 1C), this revealing the speciﬁc pro-survival
action of CXCL12 on naïve T lymphocytes.
3.2. Resting naive lymphocytes and activated lymphoblasts express compa-
rable levels of CXCR4
Next, we wanted to verify whether the speciﬁc action of CXCL12
only on naive T lymphocytes was merely due to different expression
levels of the CXCL12 receptor CXCR4 on naïve T lymphocytes compared
to proliferating lymphoblasts. In order to assess this issue, we quantiﬁed
the expression of the CXCR4membrane receptor by ﬂow cytometry and
we found that its expression levels were comparable in the two popula-
tions of cells (Fig. 2; 46,5% vs 48,6% in naïve cells and lymphoblasts,
respectively). These data exclude that the absence of CXCL12-driven
pro-survival effects on lymphoblast might be due to the absence of its
receptor.
3.3. CXCL12 does not inﬂuence naïve T lymphocytes proliferation
The increased number of naïve CD4+ T lymphocytes detected upon
CXCL12 treatment (Fig. 1) might also be due to a possible CXCL12-
mediated activation of cells and induction of proliferation. Indeed, a
Fig. 1.CXCL12promotes CD45RA+CD4+T lymphocytes survival. A, Resting naive CD4+T lymphocyteswere separated fromPBMC by negative selection, using immunomagnetic beads.
Cells were cultured in a nutrient-poor medium (2% FBS) in the presence or absence of CXCL12 (100 ng/ml), and harvested every other day. Cells were harvested every other day, and
stained with propidium iodide just before acquisition and analysis by ﬂow cytometry. On the left, representative dot plots of propidium iodide (PI) staining versus cell size (x axis).
Upper plots, untreated naïve cells at day 3 and day 7 of culture. Lower plots, cells treated with CXCL12. On the right, graph showing the percentage of PI negative cells over time.
CXCL12 (black circle) increased the survival of naïve cells, compared to untreated lymphocytes (open circle) at day 7 and 9, (p b 0.001, n = 6). Asterisks indicates a statistically
signiﬁcative difference of p b 0.001. B, percentage of living cells was also calculated considering size and granulosity of cells by FACS analysis. Plots on the left represent a typical
analysis of untreated (upper plots) and CXCL12 treated (lower plots) naïve cells at day 3 and day 7. CXCL12 increased cells survival at day 7 and 9, as compared to untreated controls
(p b 0.001 n = 9, graph on the right). Asterisks indicates a statistically signiﬁcative difference of p b 0.001. C, Activated lymphoblasts were obtained by stimulating for 3 days naïve
CD4 + T cells with PHA (2 μg/ml) and IL-2 (20 U/ml). Cells were then washed and cultured in nutrient-poor medium for up to 9 days. Every other day cells were harvested and their
viability was measured by ﬂow cytometry analysis, considering size and granulosity. Plots on the left represent a typical analysis at day 3 and 7; graph on the right represent analysis
of 6 independent experiments. CXCL12 (black circle) did not inﬂuence lymphoblasts survival (p = 0.8).
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been previously reported. In order to establish the real role of CXCL12
on naïve CD4+ T lymphocytes survival, we analyzed their proliferation
rate in response to anti-CD3 coated beads by measuring 3H-thymidine
incorporation in absence and presence of CXCL12. Our results showed
that CXCL12 is not able to induce a co-stimulatory signal in naïve cells
(Fig. 3). We therefore conclude that the increased number of living
cells recorded upon CXCL12 treatment is not due to cellular activation
and proliferation, but to a pro-survival effect.3.4. The anti-apoptotic proteins Bcl2 and Bcl-Xl are up-regulated by CXCL12
To verify whether the pro-survival effect of CXCL12 on naïve cells
could be due to the activation of anti-apoptotic pathways, we analyzed
byWestern Blot the expression of Bcl2 and BclXl, in CD4+ CD45RA+ T
lymphocytes treated or notwith CXCL12 for 24 or 72h. Interestingly,we
found that CXCL12 strongly enhances the expression of Bcl2. Moreover,
also the anti-apoptotic protein Bcl-Xl is up-regulated by CXCL12 (Fig. 4).
These ﬁndings clearly show that CXCL12 increases the resistance of
naïve CD4+ T lymphocytes to apoptotic death stimuli, which might
likely be the mechanism through which CXCL12 improves survival in
this cell population.Fig. 2. Expression of CXCR4 on naive and activated CD4+ T lymphocytes. CXCR4 expression
histogram) on naïve T cells (left plot) and on activated lymphoblasts (right plot). Gray histogr
Plots are representative of 6 different experiments. Bar graph shows the mean percentage of c3.5. CXCL12 effect in naïve CD4+ T lymphocytes is PKA-dependent and
mediated by the CREB activation
To better understand the mechanisms underlying the pro-survival
effect of CXCL12, we analyzed some signaling pathways that might be
associated to CXCR4 activation. In particular, since we have observed a
Bcl2 over-expression in response to CXCL12 stimulation, and since a
cAMP responsive element (CRE) sequence is present in thepromoter re-
gion of Bcl2, we decided to analyze the phosporylation and activation of
the cAMP responsive element binding protein (CREB). Interestingly, we
found that CREB is over-phosphorylated in the presence of CXCL12
(Fig. 5A; 15 min and 60 min). This over-activation is rapid and physio-
logically transient as, at longer time points, the phosphorylation is no
longer detectable both in untreated and treated cells (Fig. 5A; 18 h).
PMA and Ionomycin (P/I) were used as control for optimal lymphocytes
activation, as they activate PKC and open intracellular calcium storages.
Consistently with our above observation of the absence of CXCL12 pro-
survival effects on lymphoblasts (see Fig. 1C), we found that CXCL12
stimulation of lymphoblasts does not trigger CREB phosphorylation
(Fig. S1). This results corroborate our hypothesis that CXCL12 pro-
survival effects are mediated by CREB phosphorylation.
One of the principal activator of CREB is the cAMP-dependent pro-
tein kinase (PKA). To verify whether PKA activation is involved in thewas evaluated by ﬂow cytometry. Histogram plots show the expression of CXCR4 (open
am, isotype control. Numbers in plots indicate the percentage of CXCR4 expressing cells.
ells expressing CXCR4 (n = 10, p = 0.8).
Fig. 3. CXCL12 does not inﬂuence proliferation of naive CD4+ CD45RA+ T lymphocytes.
Naïve T cells were incubated for 72 h with anti-CD3 coated beads at different cells/beads
ratios (x axis), in the presence (black circle) or absence (open circle) of CXCL12. As a
positive control for costimulation, beads coated with anti CD28 were used (open
triangle). In the last 16 h 3H-thymidine was added and proliferation was evaluating by
counting cpm using a plate reader beta-counter. Adding of CXCL12 to anti CD3
stimulated naïve cells did not increased their proliferative response compared to control
(anti-CD3 coated beads only).
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H89, a potent cell permeable inhibitor of PKA.We observed that PKA in-
hibition reduced cells viability of naïve CD4+ T lymphocytes in a
nutrient-poor medium (Fig. 5B; H89 vs Fig. 1A; untr) thus indicating a
role for PKA in naïve CD4+ T lymphocytes viability. Moreover, H89 re-
duced cell survival even in the presence of CXCL12 (Fig. 5B; H89
CXCL12); indeed, when H89 was added to the culture, the percentage
of living cells decreased over time with a comparable kinetics in both
CXCL12 treated and untreated cells, thus indicating that CXCL12 in-
duced pro-survival effects aremediated by PKA activation (Fig. 5B). Fur-
thermore, we observed that when 8-Br-cAMP, a cell-permeable cAMP
analog that activates PKA, was added to naive cells, the percentage of
living cells at day 5 and 7 increased and was comparable to that ob-
served upon CXCL12 administration (Fig. 5C), conﬁrming that PKA acti-
vation is involved in mediating CXCL12 induced naïve T lymphocytes
survival.
Finally, we analyzed somemembers of the mitogen-activated protein
kinase (MAPK) pathway, by evaluating ERK1/2 phosphorylation and we
observed that treatment with CXCL12 did not induce ERK1/2 phosphory-
lationwhich results therefore not active in naïve cells (Fig. 5A). Consistent
with this ﬁnding, the incubation of naive cells with the ERK1/2 inhibitorFig. 4. CXCL12 induces the upregulation of Bcl2 and BclXl. CD4+ CD45RA+ resting T
lymphocytes were incubated in the presence or absence of 100 ng/ml CXCL12 for the
indicated times. Whole lysates were separated by SDS-PAGE and immunoblotted with
the reported antibodies (BclXl, Bcl2). A typical immunoblot analysis is shown.PD98059 did not inﬂuence CD4+ CD45+ T lymphocytes survival
(Fig. S2). Viceversa, interestingly, CXCL12 rapidly induced ERK phos-
phorylation in activated lymphoblasts (Fig. S1).
4. Discussion
Here, we described a novel function of CXCL12 whichwe found able
to inﬂuence naïve CD4+ T lymphocytes lifespan. Indeed, we showed
that resting naïve T cells, cultured in a nutrient poor medium, display
an increased survival when exposed to CXCL12. Naïve T lymphocytes
die rapidly ex vivo in absence of stimuli, whereas the naïve T cell pool
in vivo ismaintained longer. One possible explanation for this difference
is the homeostatic proliferation occurring in vivo, which is supported by
the evidence of the reduction in TREC amount in naïve cells during aging
[9,11]. However, our ﬁndings showing a prosurvival effect of CXCL12 on
naïve T cells suggest that also exposure to CXCL12 and subsequent
prolonged lifespan might contribute to maintenance of resting T cells.
Aftermaturation in the thymus, themajority of T cells continuously recir-
culate through the body, traveling through secondary lymphoid organs
and bone marrow. CXCL12 is abundantly produced in bone marrow and
by stromal cells in lymph nodes, where it attracts CXCR4+ B and T lym-
phocytes. Therefore, lymphocytes, circulating through bone marrow and
lymph nodes, are constantly exposed to CXCL12. Our data clearly show
that CXCL12 triggers prosurvival signals in naïve CD4+ T cells, therefore
we hypothesize that this could be an additional mechanism by which
naïve T cells compartment in vivo is kept. This hypothesis is consistent
with a recent report of the role of CXCR4 in the homeostatic self-
renewal of central memory CD8 T lymphocytes [27]. Another evidence
supporting our hypothesis comes from the observation that moderate
constant training improves immune status during aging increasing the
number of circulating naïve cells [28,29] and that physical exercise can
also upregulate the expression of CXCR4 [30].
Interestingly, our experiments showed that the prosurvival effect of
CXCL12was speciﬁc for resting naïve CD4 T cells, while we demonstrat-
ed that CXCL12 did not inﬂuence the lifespan of activated lymphoblasts.
We reasoned that this difference might be due to a different amount
of CXCL12 receptors expressed by the cells or to different signaling
pathways activated downstream CXCR4 in the two cell types. Our ex-
periments revealed that the intensity of expression of CXCR4 is com-
parable in the two populations of lymphocytes, whereas the early
signaling pathways activated upon CXCL12 exposure change very
much between them.
In the attempt to unravel the signaling triggered by CXCL12 and
enhancing naïve CD4+ T lymphocytes survival, we found that the
PKA substrate CREB is phosphorylated by CXCL12. This suggests
that a PKA- and CREB-dependent mechanism might be responsible
for the prosurvival effect of CXCL12 on naïve cells. This hypothesis
is strengthened by the absence of CREB stimulation in lymphoblasts
where the prosurvival effect is not occurring. On the same basis,
the MAPK–ERK pathway does not seem to be involved in CXCL12-
induced lifespan increase in naïve cells, as we didn't observe ERK
1,2 phosphorylation, which, by contrast, was rapidly induced by
CXCL12 in lymphoblasts where survival is not enhanced. Moreover,
the prosurvival effect of CXCL12 was completely abrogated by the
presence of H89, a cell permeable PKA inhibitor, whereas survival in-
creases when a stable cAMP analog is added to the culture. These
ﬁndings strongly indicate PKA as a key player in mediating the sur-
vival signaling induced by CXCL12.
Since PKA is activated by cAMPwhich is produced by adenyl cyclase,
our ﬁnding that, in naïve CD4+T lymphocytes, CXCL12 induces PKA ac-
tivation appears controversial with the knowledge that, according to
the classical CXCR4 downstream signaling, AC should be inhibited by
CXCL12 stimulation and consequent GαI release. This apparent inconsis-
tency could be explained by the evidence that in different cell lines the
same GPRC could be associated alternatively to GαI or Gαs, inducing dif-
ferent downstream signals when activated [31]. Moreover, activation of
Fig. 5. CXCL12 induced survival effect is mediated by CREB activation. A, naive T lymphocytes were incubated for the indicated times with CXCL12 (1 μg/ml), PMA/Ionomycin or left
untreated. The activation of CREB and ERK were analyzed by SDS-PAGE and western blot. Total ERK was used as normalizer. CXCL12 induced CREB phosphorylation in naive cells,
while ERK was not activated by CXCL12. B, on the left, graph showing the viability of CD4+ CD45RA+ naive T lymphocytes incubated for up to 9 days with or without CXCL12 in
nutrient poor medium, in which the protein kinase A (PKA) inhibitor H89 (10 μM) was added. Cells viability was measured by ﬂow cytometry, considering size and granulosity of
cells. The pro-survival effect of CXCL12 was abrogated by the presence of H89. B, on the right, the graph shows the viability of CD4+ CD45RA+ cells, cultured alone or in the presence
of CXCL12 or of 8 Br-cAMP (100 μM). The prosurvival effect of CXCL12 was mimicked by the action of 8 Br-cAMP.
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embryonic retinal ganglion cells [32], in monocytes [33] and in naïve
CD4+ lymphocytes [34], supporting our results. In addition, although
for years it has been believed that CXCL12 and CXCR4 had an exclusive
relationship, recent evidence demonstrated that CXCL12 can also bind
to the CXCR7 receptor [35,36]. CXCR7 activation might be taken in ac-
count in order to explain the unusual activation of PKA we found. This
point deserves to be further investigated, although CXCR7 does not sig-
nal through a G protein, but rather via a β-arrestin [37] dependent sig-
naling and this would not ﬁt with our observation of a PKA-dependent
induction of survival.
The different signaling pathways activated by CXCL12 on resting
naïve lymphocytes and on activated lymphoblasts also explain why, in
our experimental settings, CXCL12 did not have the costimulatory effect
on proliferation reported by other groups who showed that CXCL12 in-
creases the proliferative response of CD4+ T lymphocytes [18] being
CXCR4, with CCR5, part of the immunological synapse. This difference
is likely due to the fact that here we analyzed naïve resting CD4+
cells and not total circulating lymphocytes which include also activated
and memory cells. The effects observed in a mixed population depend
on the subpopulation present in the higher proportion and, in total
lymphocytes, naïve T cells represent a minor population whose non-
responsiveness to the costimulation exerted by CXCL12 could be masked
by the ready response from other CD4 subsets.
Taken together, our results describe a long lasting prosurvival effect
of CXCL12 on naïve T lymphocytes. This effect is mediated by early PKA
and CREB activation, and is sustained by the induction of Bcl2 and BclXl.
Further studies are needed to verify whether this mechanism could be
exploited to improve immune response where necessary, such as, in
complex patients care.
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